Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Dubsky

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2011
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factorsMartin Filipits, Margaretha Rudas, Raimund Jakesz, et al.
The Lancet. Oncology|August 13, 2019
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialCristina Saura, Dominik Hlauschek, Mafalda Oliveira, et al.
NPJ Breast Cancer|October 29, 2025
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trialsShelley Potter, Kerry Avery, Rosina Ahmed, et al.
Eclinicalmedicine|August 2, 2023
The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensusOrit Kaidar-Person, André Pfob, Oreste Davide Gentilini, et al.
The Lancet. Oncology|January 2, 2021
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolboxPeter Dubsky, Katja Pinker, Fatima Cardoso, et al.
The Lancet. Oncology|November 27, 2025
The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer-a multidisciplinary consensusAndré Pfob, Katja Pinker, Ines Vaz-Luis, et al.
Cancer Treatment Reviews|May 1, 2023
Uncertainties and controversies in axillary management of patients with breast cancerWalter P Weber, Oreste Davide Gentilini, Monica Morrow, et al.
Breast (Edinburgh, Scotland)|September 23, 2021
Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)Walter P Weber, Zoltan Matrai, Stefanie Hayoz, et al.
Breast Cancer Research and Treatment|September 6, 2018
Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomyWalter P Weber, Martin Haug, Christian Kurzeder, et al.
Breast (Edinburgh, Scotland)|April 2, 2022
Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapyWalter Paul Weber, Jane Shaw, Andrea Pusic, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2011
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factorsMartin Filipits, Margaretha Rudas, Raimund Jakesz, et al.
The Lancet. Oncology|August 13, 2019
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialCristina Saura, Dominik Hlauschek, Mafalda Oliveira, et al.
NPJ Breast Cancer|October 29, 2025
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trialsShelley Potter, Kerry Avery, Rosina Ahmed, et al.
Eclinicalmedicine|August 2, 2023
The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensusOrit Kaidar-Person, André Pfob, Oreste Davide Gentilini, et al.
The Lancet. Oncology|January 2, 2021
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolboxPeter Dubsky, Katja Pinker, Fatima Cardoso, et al.
The Lancet. Oncology|November 27, 2025
The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer-a multidisciplinary consensusAndré Pfob, Katja Pinker, Ines Vaz-Luis, et al.
Cancer Treatment Reviews|May 1, 2023
Uncertainties and controversies in axillary management of patients with breast cancerWalter P Weber, Oreste Davide Gentilini, Monica Morrow, et al.
Breast (Edinburgh, Scotland)|September 23, 2021
Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)Walter P Weber, Zoltan Matrai, Stefanie Hayoz, et al.
Breast Cancer Research and Treatment|September 6, 2018
Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomyWalter P Weber, Martin Haug, Christian Kurzeder, et al.
Breast (Edinburgh, Scotland)|April 2, 2022
Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapyWalter Paul Weber, Jane Shaw, Andrea Pusic, et al.
Pageof 10